Serum IL-33 levels have been found to be higher in patients with IGM compared to those with breast cancer, suggesting IL-33 and sST2 could serve as potential differential diagnostic markers in conjunction with radiological and pathological examinations [50]. This evidence concerns the gene IL33 and breast carcinoma.